Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.

摘要: Abstract In a European joint project carried out in 6 laboratories disease-oriented program was set up consisting of panel 7 tumor types, each represented by 4 to 8 different human lines, for secondary screening promising anticancer drugs. Human lines were selected on the basis differences histology, growth rate, and sensitivity conventional cytostatic agents. Xenografts grown s.c. nude mice, treatment started when tumors reached mean diameter mm groups mice where at least evaluable. Drugs given maximum tolerated dose. For evaluation drug efficacy, median curves drawn, specific delay treated/control × 100% calculated. Doxorubicin (8 mg/kg i.v. days 1 8) effective (treated/control 1.0) 0 2 breast cancers, 3 colorectal 5 head neck non-small cell lung small melanomas, ovarian cancer lines. Amsacrine not effective, while datelliptium (35 i.p. active against Brequinar sodium (50 1–5) showed efficacy The has been shown be feasible approach. Clinical activity doxorubicin inactivity amsacrine solid types confirmed xenograft panel. Additional drugs will studied further define reliability is this novel,